The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Major stock indexes closed higher/lower on Friday, after the week saw a flurry of events including DeepSeek scare and ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

In America, heart disease is the No. 1 killer of men and women and the leading cause of death for people of most racial and ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.